Citadel Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Citadel Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.12M	Buy	211,800 +117,800	+125%	+$2.14M	﹤0.01%	5071
2026 Q1	$1.75M	Sell	94,000 -327,600	-78%	-$5.43M	﹤0.01%	6368
2025 Q4	$5.56M	Buy	421,600 +226,000	+116%	+$2.67M	﹤0.01%	4133
2025 Q3	$1.4M	Buy	195,600 +176,700	+935%	+$9.21M	﹤0.01%	6802
2025 Q2	$892K	Buy	18,900 +9,200	+95%	+$375K	﹤0.01%	7359
2025 Q1	$379K	Sell	9,700 -8,000	-45%	-$345K	﹤0.01%	9074
2024 Q4	$958K	Buy	17,700 +7,200	+69%	+$368K	﹤0.01%	7110
2024 Q3	$529K	Sell	10,500 -4,000	-28%	-$187K	﹤0.01%	8143
2024 Q2	$638K	Sell	14,500 -10,800	-43%	-$457K	﹤0.01%	7543
2024 Q1	$1.27M	Sell	25,300 -22,500	-47%	-$1.22M	﹤0.01%	6440
2023 Q4	$2.89M	Buy	47,800 +13,700	+40%	+$706K	﹤0.01%	4704
2023 Q3	$1.94M	Buy	+34,100	New	+$1.88M	﹤0.01%	5269

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Citadel Advisors's MLTX Position: Q2 2026 in Review

Citadel Advisors increased its MoonLake Immunotherapeutics (MLTX) stake by 49% in Q2 2026, buying an estimated $11.8M and bringing the position to 1,972,893 shares worth $38.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

Citadel Advisors first reported a position in MLTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $121M in Q4 2023. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Citadel Advisors held 1,972,893 shares of MoonLake Immunotherapeutics worth $38.4M as of Q2 2026.
Citadel Advisors bought 649,165 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $11.8M.
MoonLake Immunotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1833 holding.
Citadel Advisors first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 23 quarters since.
Citadel Advisors's MoonLake Immunotherapeutics position peaked at $121M in Q4 2023.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.